A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Who May Qualify: - Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention - Have at least one diabetes-related autoantibody found at screening - Show signs of remaining beta-cell function - stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening - Weigh at least 8 kilograms (kg) (18 pounds) at screening Who Should NOT Join This Trial: - Have any other type of diabetes including gestational - Have uncontrolled high blood pressure - Have had a heart attack, heart disease, stroke, or heart failure - Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy - Have a current or recent clinically serious medical condition or infection Always talk to your doctor about whether this trial is right for you.